Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Naunyn-Schmiedeberg's Archives of Pharmacology • 2006 | View Paper
“After 4 h of incubation in the presence of adrenaline , inhibition of cAMP degradation by rolipram further increased cAMP levels by about 300% and also enhanced PDE4 activity.”
Archives of Dermatological Research • 2002 | View Paper
“Intraperitoneal administration of the phosphodiesterase type 4 (PDE4) inhibitor rolipram (1-30 mg/kg) caused a dose-dependent increase in the circulating levels of both corticosterone and adrenaline in male Balb/c mice.”
“These data suggest the release of both corticosterone and adrenaline contribute to the ability of rolipram to inhibit TNF-alpha production in mouse blood ex vivo.”